New MIMS table summarises monitoring requirements for lipid-lowering drugs

GPs can now use a handy MIMS table to check which tests are needed for patients taking statins or other hyperlipidaemia treatments.

Patients taking lipid-lowering drugs may need to be monitored for signs of myopathy and rhabdomyolysis.
Patients taking lipid-lowering drugs may need to be monitored for signs of myopathy and rhabdomyolysis.

The new quick-reference table summarises the recommended frequency of testing for creatine kinase, liver and renal function and other parameters in patients taking the following classes of lipid-lowering drugs:

  • Bile acid sequestrants (colesevelam, colestipol, colestyramine)
  • Cholesterol absorption inhibitors (ezetimibe, ezetimibe/simvastatin)
  • Fibrates (bezafibrate, ciprofibrate, fenofibrate, gemfibrozil)
  • Fibrates/statins (fenofibrate/simvastatin)
  • Acipimox (Olbetam)
  • Omega-3 (Omacor, Teromeg)
  • PCSK9 inhibitors (alirocumab, evolocumab)
  • Statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin)

Drug names link through to the full MIMS entries for more detailed prescribing information on each product.

Information is summarised from manufacturers' Summaries of Product Characteristics (SPCs), available at medicines.org.uk.

The new table is also available in the MIMS app, for easy access when at home or on the go.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...